Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.2 Increasing awareness regarding female sexual health issues
3.2.3 Growing focus towards women's health
3.2.4 Rising research & development activities
3.2.5 Increasing advancements in medical technology
3.2.6 Industry pitfalls & challenges
3.2.7 Societal stigma and taboos associated with female sexual health
3.2.8 High treatment costs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Drug, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Flibanserin
5.3 Bremelanotide
5.4 Ospemifene
5.5 Estrogen therapy
5.6 Other drugs
Chapter 6 Market Estimates and Forecast, By Disease, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Dyspareunia
6.3 Hypoactive sexual desire disorder (HSDD)
6.4 Other diseases
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Topical
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Apricus Biosciences, Inc.
10.2 Cipla Limited
10.3 Freya Pharma Solutions
10.4 GSK plc
10.5 Lawley Pharmaceuticals Pty Ltd.
10.6 Merck & Co., Inc.
10.7 Millicent Pharma Limited
10.8 Novo Nordisk
10.9 Pfizer, Inc.
10.10 Sprout Pharmaceuticals, Inc
